Richard B Meagher

Athens, GA, United States of America

Richard B Meagher

This inventor holds 8 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: University of Georgia Research Foundation Inc, Abeome Corporation. Active years: 1997-2014.

USPTO Granted Patents = 8 

% Patents Active = 62.5

 

 

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 83(Granted Patents)


Company Filing History:


Years Active: 1997-2014

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Richard B. Meagher: Innovator in Biotechnology

Introduction

Richard B. Meagher is a prominent inventor based in Athens, GA (US), known for his significant contributions to biotechnology. He holds a total of 8 patents, showcasing his innovative spirit and dedication to advancing scientific knowledge.

Latest Patents

Among his latest patents, Meagher has developed methods for the rapid production of monoclonal antibodies. This invention involves genetically altered hybridomas, myelomas, and B cells, which can be utilized to create monoclonal antibodies of interest. Another notable patent focuses on metal-resistant plants and phytoremediation of environmental contamination. This method involves producing transgenic plants that can resist metal ions, thereby aiding in the remediation of contaminated sites.

Career Highlights

Throughout his career, Richard B. Meagher has worked with esteemed organizations such as the University of Georgia Research Foundation, Inc. and Abeome Corporation. His work has significantly impacted the field of biotechnology, particularly in the areas of genetic engineering and environmental science.

Collaborations

Meagher has collaborated with notable colleagues, including Vince Laterza and Anne O. Summers, further enhancing his research and innovation efforts.

Conclusion

Richard B. Meagher's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence advancements in monoclonal antibody production and environmental remediation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…